Selected article for: "international license and vaccine development"

Author: Julian Braun; Lucie Loyal; Marco Frentsch; Daniel Wendisch; Philipp Georg; Florian Kurth; Stefan Hippenstiel; Manuela Dingeldey; Beate Kruse; Florent Fauchere; Emre Baysal; Maike Mangold; Larissa Henze; Roland Lauster; Marcus Mall; Kirsten Beyer; Jobst Roehmel; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel
Title: Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors
  • Document date: 2020_4_22
  • ID: 164yx77a_40
    Snippet: Together with currently introduced, novel serology tests, the data generated by such studies 201 may critically inform evidence-based risk evaluation, patient monitoring, adaptation of 202 containment methods, and last but not least, vaccine development. 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity......
    Document: Together with currently introduced, novel serology tests, the data generated by such studies 201 may critically inform evidence-based risk evaluation, patient monitoring, adaptation of 202 containment methods, and last but not least, vaccine development. 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and risk evaluation: 1
    • cc NC ND International license and study generate: 1
    • cc NC ND International license and vaccine development: 1, 2, 3
    • containment method and vaccine development: 1
    • evidence base and patient monitoring: 1, 2
    • evidence base and risk evaluation: 1, 2, 3
    • evidence base and study generate: 1, 2
    • evidence base and vaccine development: 1, 2
    • evidence base risk evaluation and risk evaluation: 1
    • International license and patient monitoring: 1
    • International license and risk evaluation: 1
    • International license and study generate: 1, 2
    • International license and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • patient monitoring and risk evaluation: 1, 2
    • patient monitoring and vaccine development: 1, 2
    • risk evaluation and vaccine development: 1, 2, 3, 4
    • serology test and vaccine development: 1
    • study generate and vaccine development: 1, 2, 3